Logo

uniQure N.V.

QURE

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment… read more

Healthcare

Biotechnology

9 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$54.44

Price

-6.74%

-$3.93

Market Cap

$2.987b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$14.337m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$198.995m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$3.92

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$4.003m

$584.890m

Assets

$588.893m

Liabilities

$66.697m

Debt
Debt to Assets

11.4%

-0.5x

Debt to EBITDA
Free Cash Flow

-$174.264m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases